Mavorixafor (hydrochloride)

Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 nM and 9 nM, respectively. Mavorixafor hydrochloride can be used for the study of WHIM syndrome[1].

Product Specifications

CAS Number

[880549-30-4]

Product Name Alternative

AMD-070 (hydrochloride) ; AMD-11070 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/mavorixafor-hydrochloride.html

Purity

99.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NCCCCN(CC1=NC2=CC=CC=C2N1)[C@H]3CCCC4=C3N=CC=C4.[H]Cl

Molecular Formula

C21H28ClN5

Molecular Weight

385.93

Precautions

H302, H315, H319, H335

References & Citations

[1]Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53 (8) :3376-88.|[2]Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40 (1) :303-308.